REIGNITENCT07015424
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 7 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 13 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Site contacts updated at 4 of 12 sites
Notable Primary completion pushed from Nov 2026 to Jul 2027 Show 4 more changesShow less
- Eligibility criteria revised
- Study completion pushed from Nov 2028 to Jul 2029
- Secondary endpoints: details revised at 1 of 20 entries
- Site details revised at 1 of 12 sites
- Notable Eligibility criteria expanded, about 18 words
- Trial sites expanded: 9 → 12 locations
- Secondary endpoints: details revised at 1 of 20 entries
- Minor Site details revised at 1 of 9 sitesv18
- Minor Site contacts updated at 1 of 9 sitesv17
Show 7 earlier versionsHide 7 earlier versions
- Minor Site details revised at 1 of 9 sitesv15
- Minor Start date changed from estimate of Apr 2026 to Apr 14, 2026
- Site details revised at 1 of 9 sites
- Minor Start date: Mar 2026 to Apr 2026
- Site details revised at 1 of 9 sites
- Minor Study sites: 10 to 9
- Start date: Feb 2026 to Mar 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jan 2026 to Feb 2026
- Site details revised at 10 of 10 sites
- Notable Start date: Nov 2025 to Jan 2026
- Primary completion date: Feb 2027 to Nov 2026
- Study completion date: Sep 2029 to Nov 2028
- Notable Eligibility criteria revised
- Study sites: 1 to 10
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Total Body Weight Loss
Timeframe: 6 Months post enrollment
Secondary (20)
Clinically significant weight loss
Percent TBWL at each visit
Change in A1C
Change in Insulin
Change in Fasting Glucose
Show 15 moreShow less
Change in Cholesterol
Change in LDL
Change in HDL
Change in Triglycerides
Change in Alanine transaminase (ALT)
Change in Alkaline phosphatase (ALP)
Change in Aspartate aminotransferase (AST)
Reduction in Medications for Type 2 diabetes
Reduction in Hypertension Medication
Reduction in cholesterol medication
Reduction in medications for dumping syndrome
Number of device and procedure-related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Change in Impact of Weight on Quality of Life (IWQOL LITE-CT) Quality of Life Questionnaire
Change in 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire
Change in Sigstad Score
Arms and interventions
TORe and Lifestyle Modification ArmActive comparator
Subjects will receive a TORe procedure and moderate to intensive lifestyle modification throughout the study
Lifestyle Modification ArmActive comparator
Subjects will receive moderate to intensive lifestyle modification throughout the study. At 6 months post enrollment, subjects will be eligible to receive a TORe procedure.
Devices: TORe with OverStitch
Behavioral: Intensive lifestyle modification
Sites
12 sites in 1 country